We are grateful to all the participants in the VALOR study and we're thankful that Biogen remains committed to bringing tofersen to people living with ALS though expanded access. Following the release of the preliminary data, we still have questions about what the results mean for potential approval and we will continue working with the company to learn more about the full data. We hope that the findings from this study will continue to inform the development of antisense technologies, which are a promising tool in addressing familial ALS.